International cosmetic brands frequently assume that entering the European Union requires repeating every test and rebuilding every document from the beginning.
That is not always true.
Existing safety information, stability reports, microbiological data, supplier documents and claim studies may be useful for EU market entry. The real task is to determine:
- which information is relevant
- whether it applies to the final EU product
- whether the method and documentation are adequate
- which EU-specific elements are missing
The strongest market-entry strategy is not “repeat everything”. It is:
Reuse what is scientifically valid, update what is incomplete and generate only the evidence genuinely required for the EU product.
Why US documentation is not automatically EU documentation
The United States strengthened its federal cosmetics framework through the Modernization of Cosmetics Regulation Act.
MoCRA introduced or expanded obligations relating to:
- facility registration
- product listing
- safety substantiation
- adverse-event reporting
- record keeping
The FDA states that responsible persons must maintain records supporting adequate safety substantiation. However, US law does not prescribe one specific product-safety test or an EU-style CPSR format.
The EU requires a product-specific safety assessment and CPSR prepared according to Regulation (EC) No 1223/2009 before market placement.
A US safety-substantiation file can therefore support the EU assessment without replacing it.
Why UK documentation requires a separate EU review
Great Britain now operates its own cosmetics regime.
Products placed on the Great Britain market require:
- a UK-established Responsible Person
- a PIF maintained in English
- a product safety assessment
- notification through the UK Submit Cosmetic Product Notifications service
Products placed on the EU market require an EU-based Responsible Person and notification through CPNP.
Northern Ireland follows different arrangements and remains connected to the EU framework for relevant cosmetics requirements.
A product can therefore be compliant in Great Britain without being fully prepared for EU placement.
Which existing documents may be reusable?
1. The quantitative formula
The existing formula is essential, but it must represent the exact product intended for the EU.
Review:
- ingredient identity
- concentration
- raw-material trade names
- supplier
- function
- fragrance and allergen data
- colourants
- preservatives
- UV filters
- nanomaterials
A formula prepared only with US ingredient names or supplier codes may need to be mapped to EU-relevant ingredient identities and INCI terminology.
2. Raw-material technical documents
Potentially useful documents include:
- technical data sheets
- safety data sheets
- certificates of analysis
- allergen declarations
- impurity profiles
- composition statements
- natural-origin information
- nanomaterial information
- toxicological data
The age and scope of each document matter. A generic supplier statement may not answer the safety assessor’s specific questions.
3. Stability studies
Existing stability data may be reusable where:
- the tested formula matches
- the packaging matches
- the manufacturing process is comparable
- storage conditions are relevant
- the test duration supports the intended shelf life
- acceptance criteria are documented
A study on a different fragrance, preservative system or container may have limited applicability.
4. Microbiological and challenge-test data
Existing microbiological data may support the EU file if:
- the correct product was tested
- the method is appropriate
- the laboratory report is complete
- the product category and packaging are comparable
- results remain current and representative
The review should focus on scientific suitability, not only the country in which the test was performed.
5. Packaging compatibility data
Packaging information is often weak in international product files.
The assessor may need information relating to:
- packaging material
- barrier properties
- potential migration
- product interaction
- stability
- closure system
- foreseeable contamination risks
A visual image of the packaging is not a complete packaging assessment.
6. Claim-substantiation studies
Existing instrumental, clinical, consumer or in-vitro studies may support EU claims.
However, the proposed EU wording must remain consistent with the actual evidence.
EU common criteria apply to claims made through text, names, trademarks, images and other signs, regardless of the marketing medium. Claims must be supported and consistent with evidence in the PIF.
A claim acceptable in one market may require narrower wording in another.
Which EU-specific elements are commonly missing?
An EU Responsible Person
The brand must define which EU-established person or company will assume the Responsible Person obligations.
An EU-format CPSR
Existing safety information must be assessed and organised according to the requirements of Annex I.
A complete PIF
The PIF connects the CPSR with manufacturing, product description, claim evidence and other required records.
EU-compliant labelling
The label must be reviewed for:
- Responsible Person name and address
- nominal content
- durability or period after opening
- precautions
- batch identification
- product function
- ingredient list
- country of origin for imported products
- required language
CPNP notification
The product must be notified through the EU portal before market placement. CPNP does not replace the safety and documentation review.
EU-specific ingredient review
The formula should be screened against current EU prohibitions, restrictions and positive lists.
Documented post-market processes
The Responsible Person should be prepared to manage:
- undesirable effects
- serious undesirable effects
- authority requests
- corrective measures
- recalls
- product changes
- CPSR updates
A practical document-gap analysis
An effective EU readiness assessment should classify each document as:
Reusable
The document is relevant, complete and applicable to the EU product.
Reusable with clarification
The evidence may be acceptable after obtaining further information, translations or methodological details.
Requires updating
The evidence is relevant but does not reflect the current formula, packaging, supplier or intended use.
Missing
The required information has not been generated.
Not relevant
The document does not answer an EU safety, compliance or claim question and should not drive unnecessary work.
This classification avoids both over-testing and under-documentation.
Example: a US skincare serum entering the EU
A US brand may already have:
- a quantitative formula
- stability testing
- microbial limits testing
- a consumer-perception study
- FDA product listing
- manufacturing documentation
It may still need:
- an EU ingredient and restriction review
- updated fragrance or impurity information
- a CPSR
- a full PIF
- EU label adaptation
- an EU Responsible Person
- CPNP notification
- adjustment of marketing claims
The existing evidence reduces the project workload, but it does not complete the EU process by itself.
Example: a UK cosmetic brand entering the EU
A Great Britain brand may already have:
- a UK Responsible Person
- a UK-format PIF
- safety assessment
- SCPN notification
- English label
- existing test data
The EU project may still require:
- appointment of an EU Responsible Person
- EU regulatory review of the formula
- confirmation that the safety assessment meets current EU requirements
- CPNP notification
- EU Responsible Person details on the label
- Member-State language review
- assessment of any divergence between UK and EU ingredient rules
The product should be reviewed systematically rather than assumed to be identical from a compliance perspective.
How Makrolife supports international cosmetic brands
Makrolife can review existing US, UK or international product files and create a practical EU market-entry roadmap.
Support may include:
- product classification
- document-gap analysis
- formula review
- supplier-document review
- testing strategy
- existing-report assessment
- cosmetic safety assessment
- CPSR and PIF preparation
- label and claim review
- CPNP coordination
- partner coordination
- post-launch compliance support
The objective is to minimise unnecessary duplication while building a complete, traceable EU compliance file.
Do not restart the project before reviewing what you already have
International brands often possess more useful evidence than they realise. The problem is usually that the evidence has not been mapped to EU requirements.
Submit your existing product documents for an EU Cosmetic Readiness Check from Makrolife.
